Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 74.56% is in line with its 5-year average of 69.89%, near the high end of its 5-year range (61.69%–78.70%).
0.57% above its 12-month average of 74.14%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 72.82%.
GROSS MARGIN
74.56%
GROSS MARGIN AVG TTM
74.14%
GROSS MARGIN AVG 3Y
71.89%
GROSS MARGIN AVG 5Y
69.89%
GROSS MARGIN AVG 10Y
66.89%
GROSS MARGIN AVG 15Y
65.13%
GROSS MARGIN AVG 20Y
68.47%
CURRENT VS TTM AVG
+0.57%
CURRENT VS 3Y AVG
+3.71%
CURRENT VS 5Y AVG
+6.68%
CURRENT VS 10Y AVG
+11.47%
CURRENT VS 15Y AVG
+14.48%
CURRENT VS 20Y AVG
+8.90%
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+80.95%
vs the sector median at left
Vericel Corporation
Market Cap
$2.05B
Gross Margin
74.56%
TTM Avg
74.14%
3Y Avg
71.89%
5Y Avg
69.89%
Market Cap
$2.06B
Gross Margin
100.00%
TTM Avg
-1064.88%
3Y Avg
-1783.56%
5Y Avg
-1442.31%
Market Cap
$2.06B
Gross Margin
99.55%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
-349.27%
Market Cap
$2.02B
Gross Margin
97.82%
TTM Avg
97.53%
3Y Avg
97.80%
5Y Avg
96.20%
Market Cap
$2.02B
Gross Margin
90.85%
TTM Avg
89.42%
3Y Avg
88.91%
5Y Avg
89.39%
Market Cap
$2.02B
Gross Margin
90.36%
TTM Avg
88.22%
3Y Avg
91.04%
5Y Avg
93.63%
Market Cap
$2.11B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
22.50%
5Y Avg
47.90%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vericel Corporation (VCEL) | $2.05B | 74.56% | 74.14% | 71.89% | 69.89% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | 100.00% | -1064.88% | -1783.56% | -1442.31% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | 99.55% | 100.00% | 100.00% | -349.27% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 24.57% | 22.67% | 22.13% | 21.88% |
| Alvotech (ALVO)vs › | $2.08B | 60.45% | 60.99% | 17.21% | 44.81% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 97.82% | 97.53% | 97.80% | 96.20% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | 90.85% | 89.42% | 88.91% | 89.39% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 90.36% | 88.22% | 91.04% | 93.63% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | 0.00% | 0.00% | 22.50% | 47.90% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
74.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 72.82% |
| 2026-03-31 | 72.00% |
| 2025-12-31 | 78.70% |
| 2025-09-30 | 73.46% |
| 2025-06-30 | 73.71% |
| 2025-03-31 | 68.96% |
| 2024-12-31 | 77.61% |
| 2024-09-30 | 71.93% |
| 2024-06-30 | 69.50% |
| 2024-03-31 | 68.94% |
| 2023-12-31 | 74.63% |
| 2023-09-30 | 67.15% |
| 2023-06-30 | 65.20% |
| 2023-03-31 | 64.66% |
| 2022-12-31 | 72.59% |
| 2022-09-30 | 65.45% |
| 2022-06-30 | 61.69% |
| 2022-03-31 | 65.01% |
| 2021-12-31 | 71.51% |
| 2021-09-30 | 64.04% |
| 2021-06-30 | 68.09% |
| 2021-03-31 | 66.49% |
| 2020-12-31 | 74.39% |
| 2020-09-30 | 69.66% |
| 2020-06-30 | 56.73% |
| 2020-03-31 | 62.81% |
| 2019-12-31 | 73.13% |
| 2019-09-30 | 69.43% |
| 2019-06-30 | 65.50% |
| 2019-03-31 | 60.39% |
| 2018-12-31 | 72.46% |
| 2018-09-30 | 63.81% |
| 2018-06-30 | 59.36% |
| 2018-03-31 | 57.47% |
| 2017-12-31 | 64.07% |
| 2017-09-30 | 49.61% |
| 2017-06-30 | 54.76% |
| 2017-03-31 | 24.06% |
| 2016-12-31 | 54.06% |
| 2016-09-30 | 37.27% |
| 2016-06-30 | 43.07% |
| 2016-03-31 | 53.50% |
| 2015-12-31 | 53.12% |
| 2015-09-30 | 40.12% |
| 2015-06-30 | 49.22% |
| 2015-03-31 | 48.68% |
| 2014-12-31 | 54.09% |
| 2014-09-30 | 42.72% |
| 2014-06-30 | -13.02% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 87.50% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 66.67% |
| 2013-03-31 | 75.00% |
| 2012-12-31 | 78.95% |
| 2012-09-30 | 77.78% |
| 2012-06-30 | 0.00% |
| 2012-03-31 | 0.00% |
| 2011-12-31 | 89.68% |
| 2011-09-30 | 77.78% |
| 2011-06-30 | 0.00% |
| 2011-03-31 | 77.78% |
| 2010-12-31 | 0.00% |
| 2010-09-30 | 0.00% |
| 2010-06-30 | 261.90% |
| 2010-03-31 | 0.00% |
| 2009-12-31 | 87.50% |
| 2009-09-30 | 56.16% |
| 2009-06-30 | 5.80% |
| 2009-03-31 | 56.90% |
| 2008-12-31 | 35.71% |
| 2008-09-30 | 85.19% |
| 2008-06-30 | 83.22% |
| 2008-03-31 | 85.15% |
| 2007-12-31 | 98.81% |
| 2007-09-30 | 100.00% |
| 2007-06-30 | 92.73% |
| 2007-03-31 | 94.57% |
| 2006-12-31 | 98.10% |
| 2006-09-30 | 100.00% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | 99.16% |
| 2005-12-31 | 96.58% |
| 2005-09-30 | 97.22% |
| 2005-06-30 | 91.67% |
| 2005-03-31 | 65.87% |
| 2004-12-31 | 89.57% |
| 2004-09-30 | 91.98% |
| 2004-06-30 | 97.62% |
| 2004-03-31 | 98.80% |
| 2003-12-31 | 98.67% |
| 2003-09-30 | 11.67% |
| 2003-06-30 | -80.57% |
| 2003-03-31 | 26.60% |
| 2002-12-31 | -64.91% |
| 2002-09-30 | 5.38% |
